Marcus Lefebure
Hypetex (United Kingdom)(GB)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research, Immunodeficiency and Autoimmune Disorders, Protein Degradation and Inhibitors
Most-Cited Works
- → Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study(2020)215 cited
- → Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy(2012)207 cited
- → Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab(2022)145 cited
- → CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo(2014)142 cited
- → BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members(2016)73 cited
- → Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)(2020)58 cited
- → Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene(2017)54 cited
- → Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen(2022)52 cited
- → Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma(2013)47 cited
- → The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL(2025)31 cited